Poseida Therapeutics (NASDAQ:PSTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note released on Thursday, Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.

Poseida Therapeutics Trading Up 2.9 %

NASDAQ:PSTX opened at $2.87 on Thursday. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 0.56. The stock’s fifty day moving average price is $2.96 and its two-hundred day moving average price is $2.95. Poseida Therapeutics has a 52-week low of $1.54 and a 52-week high of $4.27.

Poseida Therapeutics (NASDAQ:PSTX) last released its earnings results on Thursday, March 7th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.09. The company had revenue of $25.00 million during the quarter, compared to the consensus estimate of $12.50 million. Poseida Therapeutics had a negative return on equity of 94.90% and a negative net margin of 190.76%. On average, research analysts forecast that Poseida Therapeutics will post -1.77 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Silverarc Capital Management LLC lifted its holdings in Poseida Therapeutics by 21.1% in the third quarter. Silverarc Capital Management LLC now owns 3,567,985 shares of the company’s stock valued at $8,492,000 after buying an additional 622,037 shares during the period. Public Employees Retirement System of Ohio bought a new stake in shares of Poseida Therapeutics during the 4th quarter valued at $76,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Poseida Therapeutics by 10.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 259,929 shares of the company’s stock valued at $619,000 after purchasing an additional 23,960 shares during the period. Strs Ohio bought a new position in shares of Poseida Therapeutics in the 3rd quarter worth $47,000. Finally, Barclays PLC grew its stake in shares of Poseida Therapeutics by 40.7% during the third quarter. Barclays PLC now owns 45,542 shares of the company’s stock worth $109,000 after purchasing an additional 13,174 shares during the period. Institutional investors own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.